DE69532804D1 - Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis - Google Patents

Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis

Info

Publication number
DE69532804D1
DE69532804D1 DE69532804T DE69532804T DE69532804D1 DE 69532804 D1 DE69532804 D1 DE 69532804D1 DE 69532804 T DE69532804 T DE 69532804T DE 69532804 T DE69532804 T DE 69532804T DE 69532804 D1 DE69532804 D1 DE 69532804D1
Authority
DE
Germany
Prior art keywords
amyloidosis
maillard reaction
treating diseases
reaction inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69532804T
Other languages
English (en)
Other versions
DE69532804T2 (de
Inventor
Camilo Colaco
Bruce Joseph Roser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Drug Delivery Ltd
Original Assignee
Elan Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10753465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69532804(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Drug Delivery Ltd filed Critical Elan Drug Delivery Ltd
Publication of DE69532804D1 publication Critical patent/DE69532804D1/de
Application granted granted Critical
Publication of DE69532804T2 publication Critical patent/DE69532804T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69532804T 1994-04-13 1995-04-13 Verwendung von hemmern der maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis Expired - Fee Related DE69532804T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9407305A GB2288732B (en) 1994-04-13 1994-04-13 Pharmaceutical compositions
GB9407305 1994-04-13
PCT/GB1995/000843 WO1995028151A1 (en) 1994-04-13 1995-04-13 Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease

Publications (2)

Publication Number Publication Date
DE69532804D1 true DE69532804D1 (de) 2004-05-06
DE69532804T2 DE69532804T2 (de) 2005-02-10

Family

ID=10753465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532804T Expired - Fee Related DE69532804T2 (de) 1994-04-13 1995-04-13 Verwendung von hemmern der maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis

Country Status (11)

Country Link
US (2) US5891873A (de)
EP (1) EP0755249B1 (de)
JP (1) JPH09512005A (de)
AT (1) ATE262895T1 (de)
AU (1) AU2219795A (de)
DE (1) DE69532804T2 (de)
DK (1) DK0755249T3 (de)
ES (1) ES2216012T3 (de)
GB (1) GB2288732B (de)
PT (1) PT755249E (de)
WO (1) WO1995028151A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE220327T1 (de) * 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5780513A (en) * 1996-08-22 1998-07-14 Washington University Method of inhibiting the release of bioactive IL-1
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
JPH1143432A (ja) * 1997-07-25 1999-02-16 Biremo Sci:Kk 脳の老化抑制及び治療剤
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
EP1053749A4 (de) * 1998-02-03 2003-01-15 Senju Pharma Co Vorbeuge- und heilmittel für neurodegenerative erkrankungen
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
CA2378953A1 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
MXPA02001323A (es) 2000-05-10 2004-07-16 Alliance Pharma Microgranulos con base fosfolipida para la liberacion de farmaco.
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds
ATE508735T1 (de) 2001-12-19 2011-05-15 Novartis Ag Pulmonale verabreichung von aminoglykosiden
MX2007014148A (es) * 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (de) * 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
JP7171560B2 (ja) 2017-06-07 2022-11-15 天野エンザイム株式会社 ラクターゼ原末及びラクターゼ製剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325936A3 (de) * 1988-01-16 1990-01-17 Ono Pharmaceutical Co., Ltd. Aminoguanidin-Derivate und für die Maillardreaktion inhibitorische Substanzen, die sie als aktive Inhaltsstoffe enthalten
JPH03161441A (ja) * 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
IL96486A (en) * 1989-11-28 1995-03-30 Syntex Inc Preparation tricyclic compounds and pharmaceutical preparations containing them
KR920700632A (ko) * 1990-02-19 1992-08-10 요시다 쇼오지 메일라드 반응저해제
DE69133065T2 (de) * 1990-03-02 2003-02-27 Oregon State Tri- und tetra-substituierte guanidine und deren verwendung als antagonisten von exzitatorischen aminosäuren
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE288262T1 (de) * 1991-02-08 2005-02-15 Scion Pharmaceuticals Inc Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung
TW221689B (de) * 1991-08-27 1994-03-11 Otsuka Pharma Co Ltd
US5453514A (en) * 1992-12-25 1995-09-26 Yamanouchi Pharmaceutical Co., Ltd. Pyrazole derivatives and compositions and methods of use as maillard reaction inhibitors
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0755249A1 (de) 1997-01-29
ATE262895T1 (de) 2004-04-15
EP0755249B1 (de) 2004-03-31
PT755249E (pt) 2004-08-31
US5891873A (en) 1999-04-06
JPH09512005A (ja) 1997-12-02
GB2288732B (en) 1998-04-29
WO1995028151A1 (en) 1995-10-26
GB9407305D0 (en) 1994-06-08
AU2219795A (en) 1995-11-10
DK0755249T3 (da) 2004-07-26
GB2288732A (en) 1995-11-01
US6034080A (en) 2000-03-07
ES2216012T3 (es) 2004-10-16
DE69532804T2 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
ATE270556T1 (de) Verwendung von synergistischen zusammensetzungen von il-12 und ifn-alpha für die behandlung von infektiösen krankheiten
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
ATE186305T1 (de) Perfluoroalkyll ketone, inhibitoren von elastase und prozess zur deren herstellung
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE69304843D1 (de) Methode zur Behandlung von Haarausfall
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee